|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial of TG103 Injection Monotherapy Subjects With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo-parallel, multicenter phase 3 clinical trial to evaluate the efficacy of TG103 injection 7.5mg and 15mg once a week monotherapy compared with placebo in subjects with type 2 diabetes with poor glycemic control after diet and exercise.
A Multicenter, Randomized, Open-label, Controlled Phase 3 Trial of TG103 Injection in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
This is a randomized, open-label, dulaglutide-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of different doses of TG103 injection in combination with metformin in subjects with type 2 diabetes with poor glycemic control treated with metformin monotherapy.
TG103 注射液治疗非糖尿病超重/肥胖的多中心、随机、双盲、安慰剂对照的Ⅱ期临床试验
[Translation] A multi-center, randomized, double-blind, placebo-controlled phase II clinical trial of TG103 injection for the treatment of non-diabetic overweight/obesity
评价TG103注射液在非糖尿病超重/肥胖受试者中的减重疗效、安全性、药代动力学特征和免疫原性。
[Translation] To evaluate the weight loss efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection in non-diabetic overweight/obese subjects.
100 Clinical Results associated with CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd.
100 Deals associated with CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd.
100 Translational Medicine associated with CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd.